262 related articles for article (PubMed ID: 33729654)
1. Response-based modification of CHOP chemotherapy for canine B-cell lymphoma.
Benjamin SE; Sorenmo KU; Krick EL; Salah P; Walsh KA; Weinstein NM; Keuler NS; Avery AC; Atherton MJ; Lenz JA
Vet Comp Oncol; 2021 Sep; 19(3):541-550. PubMed ID: 33729654
[TBL] [Abstract][Full Text] [Related]
2. CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma.
Rebhun RB; Kent MS; Borrofka SA; Frazier S; Skorupski K; Rodriguez CO
Vet Comp Oncol; 2011 Mar; 9(1):38-44. PubMed ID: 21303452
[TBL] [Abstract][Full Text] [Related]
3. Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma.
Wang SL; Lee JJ; Liao AT
Can Vet J; 2016 Mar; 57(3):271-6. PubMed ID: 26933263
[TBL] [Abstract][Full Text] [Related]
4. Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link?
Wang SL; Lee JJ; Liao AT
Vet J; 2016 Jul; 213():87-9. PubMed ID: 27240922
[TBL] [Abstract][Full Text] [Related]
5. Substitution of mitoxantrone for doxorubicin in a multidrug chemotherapeutic protocol for first-line treatment of dogs with multicentric intermediate- to large-cell lymphoma.
Marquardt TM; Lindley SES; Smith AN; Cannon CM; Rodriguez CO; Thamm DH; Childress MO; Northrup NC
J Am Vet Med Assoc; 2019 Jan; 254(2):236-242. PubMed ID: 30605381
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma.
Burton JH; Garrett-Mayer E; Thamm DH
Vet Comp Oncol; 2013 Dec; 11(4):306-15. PubMed ID: 22548975
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of flow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with naïve B-cell lymphoma treated with a 19-week CHOP protocol.
Wolf-Ringwall A; Lopez L; Elmslie R; Fowler B; Lori J; Sfiligoi G; Skope A; Arnold E; Hughes KL; Thamm DH; Ehrhart EJ; Avery AC; Lana SE
Vet Comp Oncol; 2020 Sep; 18(3):342-352. PubMed ID: 31682319
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of neutrophilia as a prognostic factor in dogs with multicentric lymphoma treated with a cyclophosphamide, doxorubicin, vincristine, and prednisone-based chemotherapy protocol.
Veluvolu S; Pellin M; Vos N
J Am Vet Med Assoc; 2021 Sep; 259(5):494-502. PubMed ID: 34388019
[TBL] [Abstract][Full Text] [Related]
9. Comparison of combination l-asparaginase plus CHOP or modified MOPP treatment protocols in dogs with multi-centric T-cell or hypercalcaemic lymphoma.
Angelo G; Cronin K; Keys D
J Small Anim Pract; 2019 Jul; 60(7):430-437. PubMed ID: 30790291
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of factors affecting clinical outcome following CHOP-based chemotherapy in dogs with primary nodal diffuse large B-cell lymphoma.
Childress MO; Ramos-Vara JA; Ruple A
Vet Comp Oncol; 2018 Mar; 16(1):E159-E168. PubMed ID: 29152834
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of clinical presentation, induction and rescue treatment in 42 cases of canine centroblastic diffuse large B-cell multicentric lymphoma in the United Kingdom.
Davies O; Szladovits B; Polton G; Garden OA; Leo C; Lara-Garcia A
Vet Comp Oncol; 2018 Jun; 16(2):276-287. PubMed ID: 29271043
[TBL] [Abstract][Full Text] [Related]
12. Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma.
Hosoya K; Kisseberth WC; Lord LK; Alvarez FJ; Lara-Garcia A; Kosarek CE; London CA; Couto CG
J Vet Intern Med; 2007; 21(6):1355-63. PubMed ID: 18196747
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.
Daters AT; Mauldin GE; Mauldin GN; Brodsky EM; Post GS
Vet Comp Oncol; 2010 Mar; 8(1):11-22. PubMed ID: 20230577
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).
Flory AB; Rassnick KM; Erb HN; Garrett LD; Northrup NC; Selting KA; Phillips BS; Locke JE; Chretin JD
J Am Vet Med Assoc; 2011 Feb; 238(4):501-6. PubMed ID: 21320021
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol.
Curran K; Thamm DH
Vet Comp Oncol; 2016 Aug; 14 Suppl 1():147-55. PubMed ID: 26279153
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
[TBL] [Abstract][Full Text] [Related]
17. Asparaginase and MOPP treatment of dogs with lymphoma.
Brodsky EM; Maudlin GN; Lachowicz JL; Post GS
J Vet Intern Med; 2009; 23(3):578-84. PubMed ID: 19645842
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of doxorubicin and prednisone as first-line therapy for canine B-cell lymphoma.
Al-Nadaf S; Rebhun RB; Curran KM; Venable RO; Skorupski KA; Willcox JL; Burton JH
BMC Vet Res; 2018 Nov; 14(1):356. PubMed ID: 30458771
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
[TBL] [Abstract][Full Text] [Related]
20. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
